Perioperative Tislelizumab Plus Chemotherapy for Resectable Thoracic Oesophageal Squamous Cell Carcinoma
Conditions: Esophageal Squamous Cell Carcinoma; Neoadjuvant Chemoimmunotherapy; Adjuvant Therapy Intervention: Drug: Tislelizumab Sponsor: Guo Xufeng Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Cancer & Oncology | Carcinoma | Chemotherapy | Esophagus Cancer | Research | Skin Cancer | Squamous Cell Carcinoma